IL17A and melanoma: We found that several IL-17-inducing genes were expressed at higher levels in BRAF-mutant than in BRAF-WT tumors in the SKCM cohort and that their expression was significantly decreased in MAPK inhibitor (MAPKi)-treated melanoma tissue biopsies13–15 (Extended Data Fig. 1c,d).